Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $3.4 million.

  • X4 Pharmaceuticals' Change in Accured Expenses rose 209112.43% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$853000.0, marking a year-over-year decrease of 30426.54%. This contributed to the annual value of $7.2 million for FY2024, which is 34583.33% up from last year.
  • Per X4 Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $3.4 million for Q3 2025, which was up 209112.43% from $227000.0 recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Change in Accured Expenses high stood at $4.5 million for Q2 2023, and its period low was -$7.8 million during Q1 2025.
  • For the 5-year period, X4 Pharmaceuticals' Change in Accured Expenses averaged around $433578.9, with its median value being $627000.0 (2023).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 254029.85% in 2022, then plummeted by 71566.46% in 2025.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Change in Accured Expenses stood at -$1.2 million in 2021, then surged by 304.59% to $2.5 million in 2022, then crashed by 261.85% to -$4.0 million in 2023, then skyrocketed by 182.54% to $3.3 million in 2024, then grew by 0.84% to $3.4 million in 2025.
  • Its Change in Accured Expenses stands at $3.4 million for Q3 2025, versus $227000.0 for Q2 2025 and -$7.8 million for Q1 2025.